13-cis Retinoic Acid (Isotretinoin) and Sperm Production (ARESPERM)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Sarah Hustache
- Phone Number: 0388116768
- Email: dpidrci@chru-strasbourg.fr
Study Contact Backup
- Name: Marius Teletin, MD
- Email: marius.teletin@chru-strasbourg.fr
Study Locations
-
-
-
Schiltigheim, France, 67300
- CECOS Alsace Strasbourg
-
Contact:
- Marius Teletin, MD
- Phone Number: 03 69 55 35 30
- Email: marius.teletin@chru-strasbourg.fr
-
Contact:
- Marius Teletin, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects will be infertile men (no pregnancy with partner with normal cycles and normal hysterosalpingogram despite >1 year of unprotected intercourse).
- Abnormal sperm analyses with a total, motile sperm count of less than 10 million sperm as assessed by semen analysis on two occasions separated by one week.
- Male patients aged 21-55 years
- Affiliation with a social security system
- Ability to provide informed consent
Exclusion Criteria:
- -Men participating in another clinical trial
- Clinically significant abnormal findings at screening
- Known genetic infertility (e.g. Klinefelter syndrome or Y-chromosome microdeletions),
- Hypogonadotropic hypogonadism (that might respond to gonadotropin injections),
- Severe mental health problems requiring medications
- Current therapy with retinoic acid (e.g. Accutane) or vitamin A.
- History of psychiatric disorders (e.g., depression, suicidal tendencies).
- Abnormal serum chemistry values according to local laboratory normal values which indicate liver or kidney dysfunction.
- Men currently receiving tetracycline containing medications
- Men who have used isotretinoin within eight weeks of the start of dosing
- Men with elevated serum triglycerides
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Isotretinoin
Isotretinoin (40 mg) orally, once per week for 20 weeks
|
ARESPERM is a multicenter, randomized, double-blind, placebo-controlled study that assesses whether a weekly dose of isotretinoin can stimulate spermatogenesis in men with oligozoospermia.
The study hypothesizes that isotretinoin can trigger the differentiation of spermatogonial cells, leading to improved sperm production.
|
|
Placebo Comparator: control group
Placebo identical in appearance and administration schedule.
|
placebo administration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Millions of Sperm Per Ejaculate
Time Frame: Day 0
|
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
|
Day 0
|
|
Millions of Sperm Per Ejaculate
Time Frame: Months 2
|
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
|
Months 2
|
|
Millions of Sperm Per Ejaculate
Time Frame: Months 5
|
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
|
Months 5
|
|
Millions of Sperm Per Ejaculate
Time Frame: Months 12
|
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
|
Months 12
|
|
Millions of Sperm Per Ejaculate
Time Frame: Months 24
|
Concentration calculation of Millions of sperm per ejaculate in men treated with 13-cis retinoic acid
|
Months 24
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 7345
- 2024-519644-33-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.